ClinicaliQ Trial Snapshot
- A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy — Active Not Recruiting • Phase III • Oncology • NCT04660344.
- Atezolizumab immunotherapy versus placebo after bladder removal surgery in patients with high-risk cancer and detectable tumour DNA.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are circulating tumour deoxyribonucleic acid (ctDNA) positive and are at high risk for recurrence following cystectomy. Conditions: Muscle-invasive Bladder Cancer Interventions: Atezolizumab, Placebo, Signatera Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 761 participants